Events
Emmanuel, Pangea’s Chief Pharma Alliances, will be meeting both new and existing pharma/biopharma connections at the BIO International Convention in Boston next week. Schedule a meeting with him through the partnering platform to learn how ENLIGHT can support the clinical development of your precision oncology programs. Looking forward to seeing you there!
Pangea will be presenting posters at the 2025 ASCO Annual Meeting in Chicago this month. Poster presentation details are as follows:
Title: Predication of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD1 inhibition directly from histopathology slides using inferred transcriptomics
Track: Developmental Therapeutics—Immunotherapy
Date/Time: June 2, 2025, 1:30pm – 4:30pm CT
Abstract: 2630
Poster Board Number: 277
Title: Validation of ENLIGHT, an AI predictor of immune checkpoint blockade (ICB) response and resistance, across the treatment span
Track: Developmental Therapeutics—Immunotherapy
Date/Time: June 2, 2025, 1:30pm – 4:30pm CT
Abstract: 2632
Poster Board Number: 279
We look forward to seeing you there!
Our CEO, Dr. Tuvik Beker, will be presenting Pangea’s posters at the AACR Annual Meeting in Chicago this month. Poster presentation details are as follows:
Title: Applying novel transcriptomics-based markers to predict response to durvalumab and olaparib in mTNBC from histopathological slidesSession Category: Clinical Research
Session Title: Predictive Biomarkers 2
Date/Time: April 27, 2025, 2:00pm – 5:00pm CT
Location: Poster Section 31
Poster Board Number: 14
Abstract Number: 729
Title: Can we overcome the scarcity of data for building predictive models in cancer?
Session Title: Predictive Biomarkers 2
Date/Time: April 27, 2025, 2:00pm – 5:00pm CT
Location: Poster Section 31
Poster Board Number: 15
Abstract Number: 730
Our Chief Pharma Alliances, Emmanuel Elalouf, will be representing Pangea at BIO-Europe Spring in Milan next month. Schedule a meeting today to learn how ENLIGHT can add value to your oncology pipeline.
Our CEO, Dr. Tuvik Beker, will be presenting a Showcase at PMWC 2025 discussing the exciting progress Pangea Biomed has been making in unlocking the promise and hope of precision oncology for patients that need it most. He will discuss how ENLIGHT is empowering oncologists to make more informed treatment decisions, leading to better patient outcomes, and how ENLIGHT is accelerating the development of targeted cancer therapies, bringing new hope to patients faster. He will also be talking about what lies ahead: recent validations of ENLIGHT-DP (our next-generation predictive biomarker based on histopathology slide images), our regulatory roadmap, and our recent commercial launch.
Our COO, Emmanuel Elalouf, attended BIO-Europe Spring 2024 to connect with leading pharma executives.
Pangea presented a poster on the predictiveness of ENLIGHT technology.
CEO Tuvik Beker gave a presentation about ENLIGHT at the ARC summit in Tel Aviv, Israel.
COO Emmanuel Elalouf attended the Bio International Convention in Boston to meet with industry leaders and executives.
Our CTO Ranit Aharonov and COO Emmanuel Elalouf attended ASCO 2023. Ranit presented two posters: one on our ENLIGHT technology and the other on the ENLIGHT-DP framework.